Skip to main content

Table 6 PTH and calcium-phosphorus metabolism.

From: Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study

Characteristics Total
(n = 1129)
CKD Stage 3
(n= 434)
CKD Stage 4
(n= 695)
Pvalue
Phosphorus (mg/dL; mean ± SD [range]) 3.7 ± 0.7 [1.7-6.7] 3.5 ± 0.6 [1.7-6.2] 3.8 ± 0.7 [1.7-6.7] 0.001
Serum phosphous within the K-DOQI target (2.8-4.6 mg/dL) (%) 85.1 86.8 83.5 0.12
Corrected calcium (mg/dL; mean ± SD [range]) 9.3 ± 0.5 [7-11.8] 9.3 ± 0.5 [7.9-11.6] 9.3 ± 0.5 [7-11.8] 0.64
Serum calcium within the K-DOQI target (8.4-9.5 md/dL) (%) 57.6 57.5 57.6 0.99
Calcium-Phosphorus product (mg/dL, mean[SD] [Range] 35 ± 6 [14-65] 33 ± 6 [17-59] 36 ± 7 [14-65] 0.002
Percentage of patients with calcium levels below normal (< 8.4 mg/dl) 3.3 2.1 4.0 NS
Percentage of patients with phosphorus levels above normal 9.4 2.6 13.6 0.001
Calcium-Phosphorus product within the K-DOQI target (< 55 mg2/dL2) (%) 98.6 99.5 98.1 0.047
i-PTH (pg/mL; mean ± SD [range]) 145 ± 116 [0-1166] 121 ± 99 [0-468] 166 ± 125 [9-1166] 0.001
Serum i-PTH within the K-DOQI target (%) [35-70 pg/mL (stage 3) or 70-110 pg/mL (stage 4)] 24.4 28.7 20.7 0.003
Meeting all four parameters according to K-DOQI guidelines (%) 10.5 12.2 9.0 0.10
Treatment with vitamin D (ergocalciferol/calcitriol) (%) 15.0 10.6 18.9 0.001
Treatment with phosphate binders (%) 19.7 11.9 26.7 0.001